Navigation Links
Ikaria Strengthens Executive Leadership Team
Date:10/2/2008

- Head of Engineering and Operations Appointed -

CLINTON, N.J., Oct. 2 /PRNewswire/ -- Ikaria Holdings, Inc. today announced the appointment of Michael Kennedy as Senior Vice President, Engineering and Operations. In this role, Kennedy will be responsible for drug-device technology strategy and development.

"Michael's extensive experience will help Ikaria strengthen its leadership in critical care as we continue to advance our pharmaceutical pipeline through a number of strategies including our strong commitment to drug-device development," said Daniel Tasse', President and CEO of Ikaria. "I am pleased to welcome Michael, who will complete our executive leadership team."

Most recently, Kennedy served as Vice President, Technology Platform Development in the Pharmaceutical and Technology Division of Baxter International Inc., where he led drug-device technology strategy and development across the organization's portfolio. Previously he led the global development of Baxter's industry-leading dialysis and transfusion therapy innovations. Kennedy's executive experience also includes senior positions at General Electric, Hollister Inc. and Comdisco Healthcare Group.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals, biologic messengers and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit http://www.ikaria.com.

CONTACT:

Samina Bari

Ikaria

(908) 238-6372

samina.bari@ikaria.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
2. Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine
3. Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair
4. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
5. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
6. Ikaria Founding Scientist Named 2007 MacArthur Fellow
7. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
8. Algenol Biofuels Further Strengthens Team With Key Appointments
9. InNexus Biotechnology Strengthens Patent Team With New Leadership
10. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
11. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseqâ„¢ ... developed with input from industry experts to ...
(Date:3/23/2017)... -- NetworkNewsWire Editorial Coverage  ... Cancer remains one of the ... care systems, in terms of costs and resources. However, as ... development of innovative and efficient therapies that demonstrate higher chances ... of cancer treatments, a growing number of patients receiving immuno-oncology ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
(Date:3/22/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on ... today that Dr. Miriam Kidron , Oramed,s ... "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," ... Peptide Therapeutics (OPT) Boston Conference in Cambridge, ...
Breaking Biology Technology:
(Date:3/2/2017)... Who risk to be deprived of its imprint in ... https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG CONFRONT EACH ... using capacitive technology represent a fast growing market, especially ... increase of 360% of the number of fingerprint sensor ... market between 2014 and 2017 (source : N+1 Singer, ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
(Date:2/28/2017)... February 28, 2017 News solutions for biometrics, ... ... from 14 to 16 March, Materna will present its ... how seamless travel is a real benefit for passengers. To ... to their passenger touch point solutions to take passengers through the ...
Breaking Biology News(10 mins):